
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Aging Neurosci.
Sec. Neurocognitive Aging and Behavior
Volume 17 - 2025 | doi: 10.3389/fnagi.2025.1506973
This article is part of the Research Topic Mild cognitive impairment and cognitive aging View all 3 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The atherogenic index of plasma (AIP) has been proposed as a novel biomarker predictor for dyslipidemia and has been linked to various diseases. In this study, we explored the relationship between AIP levels and cognitive impairment in a middle-aged and older population.Methods: This study utilized data from the China Health and Retirement Longitudinal Study (CHARLS) for 7,918 individuals aged 45 and older. The AIP was calculated as the logarithmic ratio of triglycerides to high-density lipoprotein cholesterol. To assess the relationship between the AIP and cognitive impairment, logistic regression models were employed, while restricted cubic spline analysis was conducted to explore potential non-linear associations between AIP levels and cognitive impairment.The study participants had a mean age of 58.4 ± 8.8 years, and 49.1% were female. From 2011 to 2018, 2,911 participants (36.8%) developed cognitive impairment. After adjusting for potential confounders, the AIP was found to be significantly associated with cognitive impairment. In particular, participants in the higher AIP quartiles (Q2: odds ratio [
Keywords: Atherogenic index of plasma, cognitive impairment, CHARLS, Triglycerides, HighDensity Lipoprotein Cholesterol
Received: 06 Oct 2024; Accepted: 17 Feb 2025.
Copyright: © 2025 Zhou, Han and Bai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Weimin Bai, Henan Provincial People's Hospital, Zhengzhou, 450000, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.